{
    "id": "3622a08a-dc02-ac27-e063-6394a90ac8bb",
    "indications": "adjunct therapy forms parkinsonism . useful also control extrapyramidal disorders ( except tardive dyskinesia – ) due neuroleptic drugs ( e.g . , phenothiazines ) .",
    "contraindications": "benztropine mesylate tablets used patients able take oral medication . cumulative action , therapy initiated low dose increased gradually five- six-day intervals smallest amount necessary optimal relief . increases made increments 0.5 mg , maximum 6 mg , optimal results obtained without excessive .",
    "warningsAndPrecautions": "benztropine mesylate tablets , usp available follows : 1 mg : white , oval , scored tablets , debossed `` 2326 `` one side debossed `` v `` reverse side , supplied ndc : 70518-0132-00 ndc : 70518-0132-01 packaging : 30 1 blister pack packaging : 30 1 blister pack dispense well-closed container defined usp . store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "hypersensitivity benztropine mesylate tablets . atropine-like side effects , contraindicated pediatric patients three years age , used caution older pediatric patients .",
    "ingredients": [
        {
            "name": "CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "BENZTROPINE MESYLATE",
            "code": "WMJ8TL7510"
        }
    ],
    "organization": "REMEDYREPACK INC.",
    "name": "Benztropine Mesylate",
    "effectiveTime": "20250527",
    "indications_original": "For use as an adjunct in the therapy of all forms of parkinsonism.\n                  Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see \n       \n \n  \n                        PRECAUTIONS\n                     ) due to neuroleptic drugs (e.g., phenothiazines).",
    "contraindications_original": "Benztropine mesylate tablets should be used when patients are able to take oral medication.\n                  Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five- or six-day intervals to the smallest amount necessary for optimal relief. Increases should be made in increments of 0.5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions.",
    "warningsAndPrecautions_original": "Benztropine Mesylate Tablets, USP are available as follows:\n                  1 mg: white, oval, scored tablets, debossed \"2326\" on one side and debossed \"V\" on the reverse side, supplied in\n                  NDC: 70518-0132-00\n                  NDC: 70518-0132-01\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Dispense in a well-closed container as defined in the USP.\n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Hypersensitivity to benztropine mesylate tablets.\n                  Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients."
}